74 related articles for article (PubMed ID: 26763585)
1. Magnetic resonance imaging as a potential biomarker for Parkinson's disease.
Tuite P
Transl Res; 2016 Sep; 175():4-16. PubMed ID: 26763585
[TBL] [Abstract][Full Text] [Related]
2. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
[TBL] [Abstract][Full Text] [Related]
4. The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson's disease.
Wolters AF; Heijmans M; Michielse S; Leentjens AFG; Postma AA; Jansen JFA; Ivanov D; Duits AA; Temel Y; Kuijf ML
BMC Neurol; 2020 Aug; 20(1):292. PubMed ID: 32758176
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Vesicles as Biomarkers for Parkinson's Disease: How Far from Clinical Translation?
Gualerzi A; Picciolini S; Bedoni M; Guerini FR; Clerici M; Agliardi C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256215
[TBL] [Abstract][Full Text] [Related]
6. Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).
Tuite P
Brain Sci; 2017 Jun; 7(6):. PubMed ID: 28621758
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.
Gwinn K; David KK; Swanson-Fischer C; Albin R; Hillaire-Clarke CS; Sieber BA; Lungu C; Bowman FD; Alcalay RN; Babcock D; Dawson TM; Dewey RB; Foroud T; German D; Huang X; Petyuk V; Potashkin JA; Saunders-Pullman R; Sutherland M; Walt DR; West AB; Zhang J; Chen-Plotkin A; Scherzer CR; Vaillancourt DE; Rosenthal LS
Biomark Med; 2017 May; 11(6):451-473. PubMed ID: 28644039
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Discovery in Parkinson's Disease: Present Challenges and Future Opportunities.
Li S; Le W
Neurosci Bull; 2017 Oct; 33(5):481-482. PubMed ID: 28936754
[No Abstract] [Full Text] [Related]
9. Clinical Outcome Assessments and Digital Health Technologies Supporting Clinical Trial Endpoints in Early Parkinson's Disease: Roundtable Proceedings and Roadmap for Research.
O'Hanlon CE; Farmer CM; Ryan J; Ernecoff N
Rand Health Q; 2024 Jun; 11(3):1. PubMed ID: 38855392
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
Rizzo G; Copetti M; Arcuti S; Martino D; Fontana A; Logroscino G
Neurology; 2016 Feb; 86(6):566-76. PubMed ID: 26764028
[TBL] [Abstract][Full Text] [Related]
11. Salience and Default Mode Network Coupling Predicts Cognition in Aging and Parkinson's Disease.
Putcha D; Ross RS; Cronin-Golomb A; Janes AC; Stern CE
J Int Neuropsychol Soc; 2016 Feb; 22(2):205-15. PubMed ID: 26888617
[TBL] [Abstract][Full Text] [Related]
12. HYPERGLYCAEMIC HEMIBALLISMUS: IMPLICATIONS FROM CONNECTIVITY ANALYSIS FOR COGNITIVE IMPAIRMENTS.
Kincses ZT; Vadászi D; Németh D; Janacsek K; Szabó N; Dézsi L; Babos M; Vörös E; Vécsei L
Ideggyogy Sz; 2015 Nov; 68(11-12):417-21. PubMed ID: 26821516
[TBL] [Abstract][Full Text] [Related]
13. Amplitude of low-frequency fluctuation-based regional radiomics similarity network: Biomarker for Parkinson's disease.
Shi D; Ren Z; Zhang H; Wang G; Guo Q; Wang S; Ding J; Yao X; Li Y; Ren K
Heliyon; 2023 Mar; 9(3):e14325. PubMed ID: 36950566
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Network Connectivity Reveals Markers of Response to Deep Brain Stimulation in Parkinson's Disease.
Wu C; Matias C; Foltynie T; Limousin P; Zrinzo L; Akram H
Front Hum Neurosci; 2021; 15():729677. PubMed ID: 34690721
[No Abstract] [Full Text] [Related]
15. Diagnostic Ability of Radiofrequency Ultrasound in Parkinson's Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging.
Baranauskas M; Jurkonis R; Lukoševičius A; Matijošaitis V; Gleiznienė R; Rastenytė D
Diagnostics (Basel); 2020 Oct; 10(10):. PubMed ID: 33023076
[TBL] [Abstract][Full Text] [Related]
16. Striatal shape alteration as a staging biomarker for Parkinson's Disease.
Peralta M; Baxter JSH; Khan AR; Haegelen C; Jannin P
Neuroimage Clin; 2020; 27():102272. PubMed ID: 32473544
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
[TBL] [Abstract][Full Text] [Related]
18. The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson's Disease.
Lorio S; Sambataro F; Bertolino A; Draganski B; Dukart J
Front Aging Neurosci; 2019; 11():57. PubMed ID: 30930768
[TBL] [Abstract][Full Text] [Related]
19. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
Lewis MM; Du G; Baccon J; Snyder AM; Murie B; Cooper F; Stetter C; Kong L; Sica C; Mailman RB; Connor JR; Huang X
Mov Disord; 2018 Sep; 33(9):1432-1439. PubMed ID: 29756231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
